NCT01468259View on ClinicalTrials.gov

A Multi-Center, Open-Label Study

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Renal DiseaseEnd Stage Renal Disease
Interventions
DRUG

Droxidopa

The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.

Trial Locations (1)

37920

NOCCR, Knoxville

Sponsors
All Listed Sponsors
lead

Chelsea Therapeutics

INDUSTRY